{"name":"ADC Therapeutics","slug":"adc-therapeutics","ticker":"ADCT","exchange":"NYSE","domain":"adctherapeutics.com","description":"ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase ","hq":"Lausanne, Switzerland","founded":0,"employees":"188","ceo":"Ameet Mallik","sector":"ADC Oncology","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":3.42,"stockChange":-0.06,"stockChangePercent":-1.72,"marketCap":"$435M","metrics":{"revenue":81357000,"revenueGrowth":-9.5,"grossMargin":-26.3,"rdSpend":104005000,"netIncome":-142623000,"cash":231008000,"dividendYield":0,"peRatio":-2.3,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2022-01-01","label":"Zynlonta first approved","drug":"Zynlonta","drugSlug":"loncastuximab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Zynlonta patent cliff ($0.0B at risk)","drug":"Zynlonta","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"Zynlonta patent cliff ($0.0B at risk)","drug":"Zynlonta","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ADCT-901","genericName":"ADCT-901","slug":"adct-901","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Zynlonta","genericName":"LONCASTUXIMAB","slug":"loncastuximab","indication":"relapsed or refractory large B-cell lymphoma","status":"marketed"}]}],"pipeline":[{"name":"ADCT-901","genericName":"ADCT-901","slug":"adct-901","phase":"phase_1","mechanism":"ADCT-901 is an antibody-drug conjugate that delivers a cytotoxic payload to cancer cells via targeted antibody binding.","indications":[],"catalyst":""},{"name":"Zynlonta","genericName":"LONCASTUXIMAB","slug":"loncastuximab","phase":"marketed","mechanism":"Zynlonta works by binding to a specific target on cancer cells, marking them for destruction.","indications":["relapsed or refractory large B-cell lymphoma","diffuse large B-cell lymphoma (DLBCL) not otherwise specified","DLBCL arising from low-grade lymphoma","high-grade B-cell lymphoma"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"ADC Therapeutics Announces FDA Approval of Zynlonta for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma","summary":"ADC Therapeutics announced that the FDA has approved Zynlonta for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.","drugName":"Zynlonta","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"ADC Therapeutics Reports Third Quarter 2023 Financial Results","summary":"ADC Therapeutics reported its third quarter 2023 financial results, with a net loss of $43.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"ADC Therapeutics Announces Collaboration with Merck KGaA, Darmstadt, Germany to Develop and Commercialize Zynlonta in Japan","summary":"ADC Therapeutics announced a collaboration with Merck KGaA, Darmstadt, Germany to develop and commercialize Zynlonta in Japan.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOMlNDbGZ3cW5kWGU2eUozS0FUQVlOZzFKbkR4NUxSd25Oc2kzSGdCQmZHMnlsSlRyUVVtTHY1dUE4SkltSG9obmRNajhxSXhLUmpJeVdyYmM4MklVT1BpbTJiNFM5b2F2cXVVV2Q0UHpaNDJjU0tEYjNvTTRHMG1KZTdLeU9VZk1kWDRIY2pkWTBVMTQ?oc=5","date":"2026-03-30","type":"pipeline","source":"qz.com","summary":"Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - qz.com","headline":"Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQOVBsclllQXloM0t5cDRRUDBFVE1PWE1aVGJ6WWJtVjY2bXcyTkcwR0hsNEZCMGo0NHl2T1MydEFjbml0U2tyZW8yMmFEY2pfaVBTenZoQTFWa3NQSlRvUVQ0QWhYZjJWQ0pEbzFhVmtCc091YlBvdWRTWWpCMnhaelJRSy15b3E2eHV0b3RETmp4elQtczVHV19IVXhtVUM3M1R5NmZxa25PSWph?oc=5","date":"2026-03-30","type":"pipeline","source":"Yahoo Finance","summary":"Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance","headline":"Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-05","type":"pipeline","source":"simplywall.st","summary":"ADC Therapeutics SA's (NYSE:ADCT) Price Is Right But Growth Is Lacking - simplywall.st","headline":"ADC Therapeutics SA's (NYSE:ADCT) Price Is Right But Growth Is Lacking","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxQTm9qRFRSdjNtTWdKS0gwMkIwT2R4eGF3OFBnN0tDMHg4MFBYc0tYV0hOYUluUVhieWRLdTktNTNYZjRaQVJ6eEtBV3hYeERtMnV0ZUZZelNDdHZxQk83b08takttQjlDREVFWnVFODJlWTVPU2lCMzFjS1Yxc2FwZTJCZzVVWVFZLXV4NXRJMjNvY2RSMmhvQXdFM0tCVFVEQVRtV1AzT0NlT0pVWktiZkUyV2VaVWFzcE1ZcXlTd1d4QkZEZWFBazgzM1JIVWEwaWlmQ3JqREloZ0puYm5HVUR4SkQ3RTZkTUdSLWJCeWJJd0YzenpUcVZGNGc5c0QtdWhqaDQ2clFrakU?oc=5","date":"2025-12-19","type":"pipeline","source":"Finansavisen","summary":"Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines - Finansavisen","headline":"Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPaDNjcWtpeDAzbkRMbkVhS01ZbENJelI1YjktTWZnMWljT0d2dm1wUDY1SG13d2R1emJ5MXRzOFRDbVJPZURJelhQN0tCR3ZWNExMSWxxVnhhZ29YNklYeGFKV1prUnFCMGtYR2ItTmtLNTI1djBLaDd5VHZZLXRrS3ZDSmpKZUs3VUl3?oc=5","date":"2025-12-17","type":"pipeline","source":"Yahoo Finance","summary":"Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance","headline":"Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNZW9xTTFWUDltSGo0bnZCektBcTFEd1p4NkJ3WXZPOUtNSGs4QUxmRUxnQm02ZVViZDNmc0lkZTJwNzZ4WGc1WW1CeFJHMTdPQ0c1SDdQQnZTc0V3dU51aTgxdmc4b0kxQTRKNVU1WkV6NVc0MlhZSU9OdHpwSjZmSVdaRDVjZm9HWmVRY0tYWlczRVhPcy1kSjFacFhfUUs0dU9yUFQ5dGV5QUpyLU1sYTVNZmM0S1lsVE9R?oc=5","date":"2025-06-12","type":"pipeline","source":"Fierce Biotech","summary":"ADC Therapeutics shutters UK R&D site, culls several preclinical programs and trims workforce by 30% - Fierce Biotech","headline":"ADC Therapeutics shutters UK R&D site, culls several preclinical programs and trims workforce by 30%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE82anhJb1d5NHJiOXBQQ1V3T25YWjlGMGxQNHFsWDlmbWI0eDYwY2YtaVNQcWgzaW1tbHUxYnRySHN5YWNPSHBwQ3I2M2YyTE9GS2cw?oc=5","date":"2025-06-12","type":"pipeline","source":"firstwordpharma.com","summary":"ADC Therapeutics axes 30% of staff, closes UK facility - firstwordpharma.com","headline":"ADC Therapeutics axes 30% of staff, closes UK facility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxQdEJlZERQTnZSNVJVcjdlYTdEdXJoR3ViT1pHemlRMlZNWXBIQlhxcnhoNHh2dVFJaTlLc3VhRF9kOHJ5bjRIeGlZbWRjLXA4eUhqQnJHSUNhNFRwVURIdXBSX2dIQmVLY05xbFVZSHQ1ODJmTEl3REVQV0h1RjRObTZ1T1NmRWF0Q0ItQTlvWGx5bWxzb3Fkdm1HcnhLNExqMlV5YjYxSnV3RUV4ZEJ5UElza0d6TC01RDdEcWEtYllqTTNaQUZSVjlJQXZsX0NBaHRicldYU252Tkx0MWxnVGRCYm1VMzdWUnZabmNXUU1EVzBsV2U5aEU1ZWNCV1h6dVNzSFZKdFFldE0?oc=5","date":"2025-04-28","type":"trial","source":"PR Newswire","summary":"ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025 - PR Newswire","headline":"ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5SYWE4dXB2aTBlTnhGRUh1SGNwX2lGX3dLUk95bk5abkhNejdKcmhjb0VFM1hKZDN0VHJWTmF1MkRNNFNJZjVvZ29mZGx0b0c5Y01n?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"ADCT Stock Price, News & Analysis - Stock Titan","headline":"ADCT Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOVDdHTDBVektTcEdmdm1xV0liVUFaNFVsVXNaUVJGZ2hRdS1LWUxXNkpqWW5YM01XU3lXd1B3dnQ1cld0MDN6MVpyUHRqdE91ZVNGaDdRU01xb0hhdXBjbzhiMnJJNHltRUtVNkFuVGRuc1ZtbTNUWWwyOFBEakc4TUNYWUh2M3puUDFtWEJBY0xRZUpTdTZHbVl4OTVYU3E5QzN3c3hxM3FvSU8yZ2czd05JNHZ1b2Mtb0tSVTNvb2pweVYt?oc=5","date":"2025-03-24","type":"regulatory","source":"Seeking Alpha","summary":"ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025 - Seeking Alpha","headline":"ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOMGRUWXZRdWxQX2czZUZlQTB3OWdZa3p3LUR3Q2FNN3hvMHdxMlRzOGJUTHhsWVdGaXpSNEs3d09OU3lHUGVVZFZCd0JVUUF3SkF1blVncmdBQUo0dHNTZ0NxQnVBX0xTdVhINk9qZTdHckZsazRsTXNQNm9IYkhnSGExdkdrckRBT0hpOW0xendEWkhzVy0xb0s1anpyWDl2?oc=5","date":"2022-07-08","type":"deal","source":"Fierce Pharma","summary":"In $435M deal, ADC Therapeutics taps Sobi to market Zynlonta outside of the US - Fierce Pharma","headline":"In $435M deal, ADC Therapeutics taps Sobi to market Zynlonta outside of the US","sentiment":"neutral"}],"patents":[{"drugName":"Zynlonta","drugSlug":"loncastuximab-tesirine","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"Zynlonta","drugSlug":"loncastuximab-tesirine","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"EU","annualRevenue":0}],"drugCount":2,"phaseCounts":{"phase_1":1,"marketed":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Bristol-Myers Squibb","Roche Holding","Gilead Sciences"],"therapeuticFocus":["Hematologic Malignancies","Solid Tumors"],"financials":{"source":"sec_edgar+yahoo","revenue":81357000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":81357000,"period":"2025-12-31"},{"value":70837000,"period":"2024-12-31"},{"value":70837000,"period":"2024-12-31"},{"value":69558000,"period":"2023-12-31"},{"value":69558000,"period":"2023-12-31"}],"grossProfit":75559000,"grossProfitHistory":[{"period":"2025-12-31","value":75559000},{"period":"2024-12-31","value":64888000},{"period":"2023-12-31","value":67029000},{"period":"2022-12-31","value":206607000}],"rdSpend":104005000,"rdSpendHistory":[{"period":"2025-12-31","value":104005000},{"period":"2024-12-31","value":109633000},{"period":"2023-12-31","value":127127000},{"period":"2022-12-31","value":186457000}],"sgaSpend":79933000,"operatingIncome":-107207000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-107207000},{"period":"2024-12-31","value":-129591000},{"period":"2023-12-31","value":-165051000},{"period":"2022-12-31","value":-122987000}],"netIncome":-142623000,"netIncomeHistory":[{"period":"2025-12-31","value":-142623000},{"period":"2024-12-31","value":-157846000},{"period":"2023-12-31","value":-240053000},{"period":"2022-12-31","value":-157128000}],"eps":-1.62,"epsHistory":[{"period":"2024-12-31","value":-1.62},{"period":"2023-12-31","value":-2.94},{"period":"2022-12-31","value":-1.99},{"period":"2021-12-31","value":-3}],"cash":261338000,"cashHistory":[{"period":"2025-12-31","value":261338000},{"period":"2024-12-31","value":250867000},{"period":"2023-12-31","value":278598000},{"period":"2022-12-31","value":326441000}],"totalAssets":323150000,"totalLiabilities":508984000,"totalDebt":117024000,"equity":-185834000,"operatingCashflow":-141174000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-141174000},{"period":"2024-12-31","value":-123835000},{"period":"2023-12-31","value":-118686000},{"period":"2022-12-31","value":-138311000}],"capex":-264000,"capexHistory":[{"period":"2025-12-31","value":-264000},{"period":"2024-12-31","value":-867000},{"period":"2023-12-31","value":-3216000},{"period":"2022-12-31","value":-687000}],"freeCashflow":-141438000,"dividendsPaid":null,"buybacks":-221000,"employees":188,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":22604000,"ebit":-20619000,"ebitda":-20505000,"period":"2026-03-31","revenue":20851000,"epsBasic":-0.21,"netIncome":-32968000,"rdExpense":19877000,"epsDiluted":-0.21,"grossProfit":17236000,"operatingIncome":-25245000},{"sga":21442000,"ebit":6201000,"ebitda":6314000,"period":"2025-12-31","revenue":23058000,"epsBasic":-0.04,"netIncome":-6409000,"rdExpense":18184000,"epsDiluted":-0.04,"grossProfit":21359000,"operatingIncome":-18123000},{"sga":19014000,"ebit":-27574000,"ebitda":-27452000,"period":"2025-09-30","revenue":16427000,"epsBasic":-0.3,"netIncome":-40966000,"rdExpense":26803000,"epsDiluted":-0.3,"grossProfit":15225000,"operatingIncome":-30326000},{"sga":18969000,"ebit":-42395000,"ebitda":-41213000,"period":"2025-06-30","revenue":18839000,"epsBasic":-0.5,"netIncome":-56646000,"rdExpense":30090000,"epsDiluted":-0.5,"grossProfit":18003000,"operatingIncome":-30575000},{"sga":20508000,"ebit":-26207000,"ebitda":-25748000,"period":"2025-03-31","revenue":23033000,"epsBasic":-0.36,"netIncome":-38602000,"rdExpense":28928000,"epsDiluted":-0.36,"grossProfit":20972000,"operatingIncome":-28183000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3.42,"previousClose":3.48,"fiftyTwoWeekHigh":4.98,"fiftyTwoWeekLow":1.69,"fiftyTwoWeekRange":"1.69 - 4.98","fiftyDayAverage":3.95,"twoHundredDayAverage":3.79,"beta":1.84,"enterpriseValue":647877248,"forwardPE":-2.3,"priceToBook":-2.01,"priceToSales":5.49,"enterpriseToRevenue":8.18,"enterpriseToEbitda":-6.35,"pegRatio":0,"ebitda":-102036752,"ebitdaMargin":-128.9,"freeCashflow":-74853000,"operatingCashflow":-114550000,"totalDebt":436260000,"debtToEquity":0,"currentRatio":4.09,"returnOnAssets":-22.7,"returnOnEquity":0,"analystRating":"1.2 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":5,"targetMeanPrice":8.2,"targetHighPrice":10,"targetLowPrice":6,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":13.2,"institutionHeldPercent":67.2,"sharesOutstanding":127191158,"floatShares":100412332,"sharesShort":5474173,"shortRatio":5.94,"shortPercentOfFloat":4.3,"epsTrailing":-0.97,"epsForward":-1.49,"revenuePerShare":0.62,"bookValue":-1.7,"officers":[{"age":52,"name":"Dr. Ameet  Mallik M.B.A., M.S.","title":"CEO & Director"},{"age":53,"name":"Mr. Jose I. Carmona M.B.A.","title":"Chief Financial Officer"},{"age":60,"name":"Dr. Mohamed  Zaki M.D., Ph.D.","title":"Chief Medical Officer"},{"age":null,"name":"Ms. Lisa Michelle Kallebo","title":"Corporate Controller & Chief Accounting Officer"},{"age":51,"name":"Dr. David S. Ege Ph.D.","title":"Chief Technical Officer"},{"age":null,"name":"Ms. Nicole  Riley","title":"Head of Investor Relations & Corporate Communications"},{"age":58,"name":"Mr. Peter J. Graham Esq.","title":"Secretary and Chief Legal & Compliance Officer"},{"age":58,"name":"Ms. Kimberly  Pope","title":"Senior VP & Chief People Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.adctherapeutics.com","phone":"41 21 653 02 00"}}